Cooper Companies (NASDAQ:COO - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday, Wall Street Zen reports.
Several other equities analysts have also recently issued reports on COO. UBS Group dropped their price objective on shares of Cooper Companies from $75.00 to $66.00 and set a "neutral" rating on the stock in a research note on Thursday, September 10th. Citigroup restated a "neutral" rating and issued a $60.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Barclays upgraded shares of Cooper Companies to a "hold" rating in a research note on Wednesday, October 7th. Wells Fargo & Company set a $61.00 target price on shares of Cooper Companies and gave the company an "equal weight" rating in a report on Thursday, September 10th. Finally, Piper Sandler reiterated a "neutral" rating on shares of Cooper Companies in a research note on Thursday, October 15th. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $68.60.
Get Our Latest Report on Cooper Companies
Cooper Companies Stock Down 2.5%
COO opened at $58.84 on Friday. Cooper Companies has a 52 week low of $51.01 and a 52 week high of $89.83. The business has a 50 day moving average price of $58.36 and a two-hundred day moving average price of $67.65. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. The company has a market cap of $11.19 billion, a PE ratio of 20.08, a P/E/G ratio of 2.43 and a beta of 0.83.
Cooper Companies (NASDAQ:COO - Get Free Report) last announced its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period last year, the business posted $0.49 EPS. The company's revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts anticipate that Cooper Companies will post 4.53 EPS for the current year.
Cooper Companies declared that its Board of Directors has initiated a share buyback plan on Wednesday, September 9th that authorizes the company to repurchase $3 billion in shares. This repurchase authorization authorizes the medical device company to reacquire up to 22.7% of its shares through open market purchases. Share repurchase plans are often an indication that the company's leadership believes its stock is undervalued.
Insider Activity
In other news, Director Paul Keel purchased 4,701 shares of the firm's stock in a transaction dated Friday, September 11th. The shares were acquired at an average price of $53.18 per share, with a total value of $249,999.18. Following the purchase, the director directly owned 4,701 shares of the company's stock, valued at $249,999.18. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Lawrence Kurzius purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was purchased at an average price of $54.93 per share, for a total transaction of $549,300.00. Following the acquisition, the director owned 31,099 shares in the company, valued at approximately $1,708,268.07. This trade represents a 47.40% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 34,701 shares of company stock worth $1,880,039. Company insiders own 2.08% of the company's stock.
Institutional Trading of Cooper Companies
Institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Cooper Companies in the second quarter valued at $1,077,762,000. Generation Investment Management LLP acquired a new stake in Cooper Companies in the 2nd quarter valued at about $356,304,000. Jupiter Topco LLC acquired a new stake in Cooper Companies in the 2nd quarter valued at about $305,074,000. First Trust Advisors LP increased its holdings in Cooper Companies by 753.7% during the 3rd quarter. First Trust Advisors LP now owns 2,390,409 shares of the medical device company's stock valued at $135,130,000 after acquiring an additional 2,110,403 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in Cooper Companies during the 2nd quarter valued at about $144,125,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.
Cooper Companies Company Profile
(
Get Free Report)
CooperCompanies is a global medical device company focused on vision care and women's health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women's health and fertility care.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cooper Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cooper Companies wasn't on the list.
While Cooper Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.